Their effects on NAFLD may be due to systemic benefits upon various metabolic pathways, and not to the activation of the local GLP-1 receptors, which are not expressed in the hepatic tissue in significant amounts [92]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.